December 9, 2019Open Access
Efficacy of Empagliflozin on Heart Failure and Renal Outcomes in Patients with Atrial Fibrillation: Data from the EMPA-REG OUTCOME Trial
Structured PICO
Does empagliflozin reduce heart failure and renal events in patients with type 2 diabetes mellitus, established cardiovascular disease, and atrial fibrillation?
P
Population
Patients with type 2 diabetes mellitus and established cardiovascular disease, stratified by the presence of atrial fibrillation (AF) at baseline.
I
Intervention
Empagliflozin
O
Outcome
Heart failure-related and renal eventshard clinical
Patients with type 2 diabetes, cardiovascular disease, and atrial fibrillation derive a high absolute benefit from empagliflozin for preventing heart failure and renal events.
Abstract
In patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF-related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Michael Böhm
Heart Failure & Transplant
J
Jonathan Slawik
M
Martina Brueckmann
Heart Failure & Transplant
Journals
European Journal of Heart Failure
Actions
Institutions
University of Toronto
Heidelberg University
Charité - Universitätsmedizin Berlin
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...